Presbyopia News

Ocuphire Pharma has dosed the first participants in the VEGA-3 phase 3 clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, according to a press release.

In previous posts, I discussed the great potential for the use of AI-enabled technology for ophthalmology practice marketing, particularly in the area of marketing content production.

As Healio’s coverage of the American Society of Cataract and Refractive Surgery meeting continues, take a look at the most popular articles and videos so far.

BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, AnnMarie Hipsley, DPT, PhD, and George O. Waring IV, MD, FACS, discuss the latest advances in laser scleral microporation.

BOSTON — The use of advanced presbyopia-correcting implants is a journey for the patient, according to a speaker at the American Society of Cataract and Refractive Surgery meeting.

BOSTON — Eye drops are an “exciting” technology for presbyopia in the right candidates, but ophthalmologists must educate patients on their drawbacks, according to a speaker here.

Patients with presbyopia achieved visual acuity improvement with LNZ100 in the phase 3 CLARITY safety and efficacy trials, according to a press release from Lenz Therapeutics.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Sheri L. Rowen, MD, discusses new treatment options for patients with presbyopia.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye/Retina 2024, Rajesh K. Rajpal, MD, chief medical officer at Johnson & Johnson Vision, gives an overview of some the company’s latest innovations in IOLs.